09.01.03
Indication: Memory
Source: American Heart Association’s Asia Pacific Scientific Forum, June 2003
Research: One hundred and twenty stroke patients (75 male, 45 female) were diagnosed with mild to moderate vascular dementia lasting three months or more. Subjects were randomly assigned to receive either gastrodine or Duxila, a French drug, three times daily for 12 weeks. Both medications were dissolved in water and taken by mouth.
Results: At the end of three months, the gastrodine and Duxila groups showed similar improvements in the areas of memory orientation, calculation and language. The gastrodine group scored higher on the Blessed Behavioral Scale (BBS), including indices on behavior, activities of daily living and personality. There were also fewer side effects in the gastrodine group. Results also showed the gastrodine group improvement to be 51%, with 16 of the 70 cases showing much improvement, 20 cases with some improvement and 34 cases with no change. The improvement rate for patients treated with Duxila was 52%, with seven of the 50 cases showing much improvement, 19 cases with some improvement and 24 cases with no change.
Source: American Heart Association’s Asia Pacific Scientific Forum, June 2003
Research: One hundred and twenty stroke patients (75 male, 45 female) were diagnosed with mild to moderate vascular dementia lasting three months or more. Subjects were randomly assigned to receive either gastrodine or Duxila, a French drug, three times daily for 12 weeks. Both medications were dissolved in water and taken by mouth.
Results: At the end of three months, the gastrodine and Duxila groups showed similar improvements in the areas of memory orientation, calculation and language. The gastrodine group scored higher on the Blessed Behavioral Scale (BBS), including indices on behavior, activities of daily living and personality. There were also fewer side effects in the gastrodine group. Results also showed the gastrodine group improvement to be 51%, with 16 of the 70 cases showing much improvement, 20 cases with some improvement and 34 cases with no change. The improvement rate for patients treated with Duxila was 52%, with seven of the 50 cases showing much improvement, 19 cases with some improvement and 24 cases with no change.